EDIT’s Debt-to-Equity Ratio at 0.10: What It Means for Editas Medicine Inc’s Future

Currently, the stock price of Editas Medicine Inc (EDIT) is $10.84. In the most recent trading session, the stock underwent a significant upswing, peaking at $11.135 after opening at $9.85. The stock touched a low of $9.81 before closing at $9.78.

Editas Medicine Inc had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $11.93 on 02/03/23, while the lowest price during the same period was $6.08 on 10/23/23.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


52-week price history of EDIT Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Editas Medicine Inc’s current trading price is -9.12% away from its 52-week high, while its distance from the 52-week low is 78.29%. The stock’s price range for this period has remained between $6.08 and $11.93. The Healthcare sector company’s shares managed to surpass a trading volume of around 3.55 million for the day, which was noticeably higher compared to the shares’ average daily volume of 1.56 million over the last three months.

Financial Performance and Market Capitalization

Editas Medicine Inc (EDIT) has experienced a quarterly rise of 23.32% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 885.30M and boasts a workforce of 226 employees.

Analysts’ Ratings For Editas Medicine Inc

As of right now, 6 analysts are rating Editas Medicine Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 9 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 8.16, with a change in price of +2.69. Similarly, Editas Medicine Inc recorded 1,543,380 in trading volume during the last 100 days, posting a change of +33.01%.

EDIT Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for EDIT stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.07.

EDIT Stock Stochastic Average

As of today, the raw stochastic average of Editas Medicine Inc over the past 50 days is 94.16%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 94.09%. Additionally, the Stochastic %K and %D values for the company were 93.61% and 90.80%, respectively, over the past 20 days.

EDIT Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price increase of 22.21%. However, over the past six months, we’ve seen a weaker performance of 12.45%. The price of EDIT fallen by 72.34% over the last 30 days. And in the last five days, it has surged by 41.70%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts